Full Press Release Details
BOSTON--(BUSINESS WIRE)--Jul. 23, 2026--
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates onThursday, August 6, 2026, at4:30 pm ET.
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website,https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI®FAKZYNJA®CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visitwww.verastem.comand follow us onLinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20260723238516/en/
For Investor and Media Inquiries:Julissa VianaSenior Vice President, Corporate Communications,Investor Relations & Patient Advocacyinvestors@verastem.comormedia@verastem.com
Source: Verastem Oncology